“`html
Peptides have emerged as a trending wellness product, gaining prominence through endorsements from high-profile figures including Health and Human Services Secretary Robert F. Kennedy Jr. These compounds, which are short chains of amino acids, naturally occur in the body where they function as chemical messengers controlling various functions like blood sugar regulation and mood. While some peptides such as insulin and the weight-loss drug Ozempic have undergone rigorous testing and received FDA approval, many wellness peptides remain untested and unregulated, creating a multibillion-dollar underground market where manufacturers bypass standard safety protocols.
Recently, an FDA advisory panel voted to expand consumer access to six unapproved peptides through compounding pharmacies, which operate with less regulatory oversight than traditional pharmacies. These products are marketed for sleep improvement, wound healing, and cognitive enhancement, among other uses. Critics argue this decision lacks scientific justification, as these peptides have not completed human clinical trials. Stanford University researcher Dr. Katrin Svensson emphasized that most wellness peptides lack human evidence, have unknown proper dosages, and consumers cannot verify what they are actually receiving.
Experts note that while compounded peptides may be purer and safer than completely unregulated versions found online, approval for compounding does not equate to FDA approval for safety or effectiveness. The advisory panel’s decision represents a reversal of the FDA’s 2023 restriction on these compounds. Researchers caution that increased accessibility does not lower the scientific evidence bar or eliminate risks associated with long-term use or interactions with other medications.
“`
Originally reported by Livescience →
About the Author
